About Peptilogics
Peptilogics is a surgical therapeutics company dedicated to curing and preventing devastating medical device-related infections (MDRI). Our lead candidate, PLG0206, is a first-in-class drug that targets biofilm, a protective bacterial matrix that is the root cause of device infections across surgical categories, and has no approved cure to date. PLG0206 is currently being evaluated in a Phase 2/3 registration trial for the treatment of prosthetic joint infection (PJI), the first of multiple potential indications to treat and prevent MDRI.
About Peptilogics: Leaders in Scalable, Rational Design
Peptilogics is a surgical therapeutics company dedicated to curing and preventing devastating medical device-related infections (MDRI). Our lead candidate, PLG0206, is a first-in-class drug that targets biofilm, a protective bacterial matrix that is the root cause of device infections across surgical categories and has no approved cure to date. PLG0206 is currently being evaluated in a Phase 2/3 registration trial for the treatment of prosthetic joint infection (PJI), the first of multiple potential indications to treat and prevent MDRI.
Position Overview
The Chief Financial Officer is a key member of Peptilogics' executive leadership team, accountable for all financial, accounting, treasury, and investor-relations activities. This is a lean, highly collaborative team, so the CFO must balance strategy with selective hands-on execution, knowing where to lean in personally and where to empower the team or bring in outside resources. The CFO will drive the company's capitalization strategy and scale its financial operations, shaping the systems, people, and processes that carry Peptilogics from late-stage development toward commercial growth. The role frequently leads transactions, including M&A, licensing, and strategic partnerships, and works closely with the CEO, senior leadership, and Board in a fast-moving, innovative environment.
Essential Functions
Lead all financial, accounting, treasury, and investor-relations activities with strong financial discipline and transparency
Develop and execute a financing strategy aligned with Peptilogics' growth and commercialization plans; drive capital formation and fundraising in partnership with the CEO
Oversee financial planning, reporting, tax compliance, and internal controls to meet evolving regulatory and stakeholder requirements
Build scalable financial operations to support pharmaceutical R&D, clinical development, and future commercial activity, including working-capital management, cost optimization, and cash forecasting
Lead development and management of annual corporate and departmental budgets
Oversee audit preparation and ensure timely, accurate, and compliant financial audits
Manage equity administration, including stock-option accounting and reporting
Coordinate with insurance providers to optimize risk-management coverage
Create and run a cadence of investor and Board communications, and help target and engage prospective new investors
Lead transactions including M&A, licensing, and strategic partnerships, partnering with business development to evaluate and execute revenue opportunities
Provide financial leadership to guide long-range planning and cross-functional growth initiatives
Collaborate with the CEO, senior leadership, and Board on corporate strategy
Support Legal, Compliance, and People teams on financial and regulatory matters
Perform other duties as assigned
Required Qualifications and Skills
Deep expertise in Life Science corporate financial strategy, planning, and capital management
Strong track record in fundraising across private and public capital markets, and in investor relations
Proven track record of transactions including mergers, acquisitions, licensing, IPOs, and strategic exits
Advanced knowledge of US GAAP, internal controls, compliance, and financial reporting
Experience building scalable systems, processes, and teams in a high-growth environment
Excellent analytical, strategic-thinking, and problem-solving abilities
Outstanding interpersonal and communication skills with internal and external stakeholders
Strong ethical judgment, professionalism, and discretion
Bachelor's degree in finance, accounting, economics, or a related field required; MBA, CPA, or equivalent advanced credential preferred
10+ years of financial leadership experience in life sciences, biotech, or pharmaceutical companies, including in clinical-stage organizations
Desirable Qualifications and Skills
Experience supporting a biotech startup through late-stage clinical development and early commercialization
Experience with top-tier investment banks and analysts across MedTech and Biopharma
Familiarity with financing structures common to venture-backed biotech, including non-dilutive mechanisms and grants
Track record preparing organizations for public-company-level readiness (governance, reporting, controls)
Strong orthopedic-industry relationships with potential strategic partners
Our Commitment to Equal Opportunity
Peptilogics is proud to be an equal opportunity employer. We make hiring decisions based on qualifications, experience, and potential, without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, age, disability, veteran status, or any other protected status. We welcome candidates from all backgrounds to apply.
Our Commitment to Equal Opportunity
Peptilogics is proud to be an equal opportunity employer. We make hiring decisions based on qualifications, experience, and potential—without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, age, disability, veteran status, or any other protected status. We welcome candidates from all backgrounds to apply.
Peptilogics is a surgical therapeutics company dedicated to curing and preventing medical device-related infections (MDRI). The company's lead candidate, PLG0206, is a first-in-class drug designed to target biofilm, a protective bacterial matrix that is the root cause of device infections across multiple surgical categories. PLG0206 is currently being evaluated in a Phase 2/3 registration trial for the treatment of prosthetic joint infection (PJI), representing the first of multiple potential indications. The company employs scalable, rational design approaches to develop treatments for infections that currently have no approved cures.
